Alex
At Best Startup Canada we track over 100,000 Canadian startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top British Columbia based Chairman operating in the Biotechnology space. If you think a Chairman is missing from this list, feel free to contact our editor on editor@beststartup.ca.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Nick Bedford
Chairman of Zymeworks
Mr. Bedford brings his expertise in business and finance to Zymeworks, after serving as Chairman of the Board of Directors of ActiveState Corporation, up to the time of its acquisition by Sophos UK. Additionally in the past, he has held senior positions at UBS Warburg, including the Frankfurt-based role as Head of German Equities. In this position he oversaw all sales and sales trading of equity products, and was responsible for the merger of UBS Germany’s equity business with SBC Warburg. Prior to this he was with UBS’ Securities division in Zurich, Tokyo, and London.
Follow Nick Bedford:
About : Zymeworks is a computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics.
Carolyn Cross
Founder, Chairman & Chief Executive Officer of Ondine Biomedical
Ms. Cross was one of the initial founders and financial supporters of Ondine Biomedical Inc. in 1999 and currently serves as the Chairman of the board and Chief Executive Officer the Company. Ms. Cross has over 18 years direct experience working with early stage companies and has 25 years experience with public market securities. Previously, Ms. Cross was responsible for managing pension, pooled, mutual and private client funds as a Vice President with Royal Bank Investment Management Inc., the fund management arm of the Royal Bank of Canada. She currently sits on the boards of a number of companies including Periowave Dental Technologies, Inc., OrGenX Biopharma Corp., and Sinuwave Technologies Corp, and sits on the Advisory Board of the McGill University Dental School. Ms Cross is a member of the Women’s Presidents Organization, the International Women’s Forum, the Toronto Society of Financial Analysts, the Courthill and Cherie Blair Foundations, and the Association for Professionals In Infection Control and Epidemiology. Ms Cross is the Founder of OrGenX Biopharma Corporation, a WEConnect certified company.
Follow Carolyn Cross:
About Ondine Biomedical: Ondine Biomedical develops non-antibiotic, anti-infective therapies for a broad spectrum of bacterial, viral, and fungal infections.
Howard J Verrico
CEO, Chairman & Founder of Sirona Biochem
Dr. Verrico obtained his medical degree from the University of Toronto in 1985 and has been a member of the College of Physicians and Surgeons of British Columbia since July 1986. Dr Verrico is currently a practicing emergency room physician. In addition, Dr. Verrico has extensive experience as a venture capitalist in the junior capital markets.
Follow Howard J Verrico:
About Sirona Biochem: Sirona Biochem is a biotechnology company developing diabetes therapeutics, as well as skin depigmenting and anti-aging agents.
Michael Westhaver
Chairman & CEO of Agro Epigenetics Corp
Follow Michael Westhaver:
About Agro Epigenetics Corp: Agro Epigenetics Corp is a canadian biotechnology company.
Julia Levy
Chairman of ImStar Therapeutics
Julia Levy has served in several key senior posts at QLT including Chief Scientific Officer and Vice President as well as President and CEO from 1995 to February 2002. Levy has also been a Director of QLT since 1983. In December 2006, Dr. Levy retired from the Board of Directors and became a Director Emerita. She was actively involved in QLT’s Scientific Advisory Board until January 2008 when she retired from QLT entirely. Under her leadership, QLT recorded the strongest period of growth in company history and earned a reputation for achieving milestones, including FDA approval for Visudyne® therapy to treat age-related blindness in April 2000. Following her doctorate degree in immunology from the University of London, Dr. Levy was awarded an Industrial Professorship in the Department of Microbiology from the University of British Columbia and is the recipient of several honorary degrees. A fellow of the Royal Society of Canada and former President of the Canadian Federation of Biological Sciences, Dr. Levy has earned numerous awards and honors including an appointment as an Officer of the Order of Canada in 2001, the Female Entrepreneur of the Year for International Business in 1998, Pacific Canada Entrepreneur of the Year in 2000 and the Future of Vision Award from the Foundation Fighting Blindness in 2001. In 2002 she received, along with Dr. David Dolphin, the Friesen-Rygiel prize for medical research and the Prix Galien Canada research award. Along with Dr. Gustav Huber of Novartis, she was presented with the 2003 Helen Keller Prize for Innovation in Eye Care. In her honor, the Julia G. Levy Professorship in Ophthalmology Chair was created at Johns Hopkins Hospital Wilmer Eye Institute in 2004, the same year she was awarded the Lifetime Achievement Award from the British Columbia Biotechnology Association. The author of many published scientific articles and a sought-after speaker, Dr. Levy currently serves as a director on a number of early-stage biotechnology company boards and on the board of the Working Opportunity Fund, a British Columbia, Canada-based venture capital firm
Follow Julia Levy:
About Creative Destruction Lab (CDL), ImStar Therapeutics: ImStar Therapeutics is a biotech company that develops treatments for patients with amyotrophic lateral sclerosis.
Frederick Sancilio
Chairman, President and CEO of Sancilio and Company
Frederick D. Sancilio is the Principle and Co-Founder of Sancilio and Company.
Follow Frederick Sancilio:
About Sancilio and Company: Sancilio and Company develops biopharmaceutical supplements and products.
GIPHY App Key not set. Please check settings